Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 12, 2001
- Drug Cost Ratio Down to Record Low of 22.8%
November 12, 2001
- WORLD NEWS IN BRIEF
November 12, 2001
- BULLETIN
November 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
November 12, 2001
- EFPIA Stresses That Reforms Are Needed to Promote Innovation
November 12, 2001
- Sankyo Planning Late PII Study on Pitavastatin in US
November 12, 2001
- REGULATORY NEWS IN BRIEF
November 5, 2001
- JABEX Calls For Policy to Make Japan Bioindustry-based Nation
November 5, 2001
- JPA Opposes Healthcare Cost Ceiling System
November 5, 2001
- Healthcare Services Incompatible with Market Economy: JMA Seminar
November 5, 2001
- Prozac, Evista to Boost Eli Lilly Japan to Enter Top 10 by 2010: President Mascarenhas
November 5, 2001
- JMA Presents Proposals for Financial Reconstruction of Health Insurance Programs
November 5, 2001
- J&J to Buy Out Kyowa Hakko's Interest in Janssen Kyowa
November 5, 2001
- PMS Is Important for Products Approved via Bridging Studies: PMDEC
November 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 5, 2001
- Drug Classification Table for Selection of Comparator Drugs Approved by Chuikyo
November 5, 2001
- Yutaka Pharmacy Ties Up with Drug Lion, Reaching Sales of \50 Bil.
November 5, 2001
- Reduction in Price Adjustment Zone Below 2% Is Inappropriate: Korosho Director
November 5, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…